SBFM

Sunshine Biopharma, Inc.
CAPPED RATING

Sunshine Biopharma, Inc. (SBFM) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B
Factor Score 3.5 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 2.6
Rev Growth YoY -1.6%
Gross Margin 30.3%
Price Return 3M -88.0%
Price Return 12M -99.2%
Catalyst Signal 0.00
Market Cap $2.1M
TTM Revenue $35.3M
Price / Sales 0.1
ROE -21.9%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.5) C (2.2) C+ (2.6) F (0.3) C+ (2.6) C (2.2)
2026-11-07 B+ (3.5) C (2.2) C+ (2.6) F (0.3) C+ (2.7) C (2.3)
2026-10-31 B (3.5) C (2.2) C+ (2.7) F (0.3) C+ (2.7) C (2.3)
2026-10-24 B (3.5) C (2.2) C+ (2.7) F (0.3) C+ (2.6) C (2.2)
2026-10-17 B (3.4) C (2.2) C+ (2.7) F (0.3) C+ (2.6) C (2.3)
Page 1 of 4